Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IVM/ALB Co-administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent signed by either the participant him/herself (≥21 years of age) or by parents and/or caregivers for children/adolescents; and written assent by child/adolescent (aged 6-20 years).~2. Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and on three follow-up assessments (approximately 3 weeks, 6 months, and 12 months later).~3. Aged ≥6 to \<= 60 years for parallel group trial and ≥6 to \<=12 years for DF study.~4. At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 100 EPG.~Exclusion Criteria:~1. No written informed consent by individual/parents and/or caregiver.~2. Presence of major systemic illnesses, e.g. severe anemia (below 80 g/l Hb according to WHO \[28\]), clinical malaria as assessed by a medical doctor (positive Plasmodium RDT and ≥38 °C ear temperature), upon initial clinical assessment.~3. History of acute or severe chronic disease (e.g. cancer, diabetes, chronic heart, liver or renal disease).~4. Recent use of anthelmintic drug (within past 4 weeks).~5. Attending other clinical trials during the study.~6. Negative or low egg count (less than 100 EPG or less than 2 out of 4 slides positive) diagnostic result for T. trichiura eggs in the stool.~7. Known allergy to study medications (i.e. albendazole and ivermectin).~8. Pregnancy or lactating in the 1st week after birth (according to WHO guidelines within LF control programs \[29\]).~9. Currently taking medication with known interaction (e.g. for albendazole: cimetidine, praziquantel and dexamethasone; for ivermectin: warfarin).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: albendazole (Type: PLACEBO_COMPARATOR): 400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
- Arm B: albendazole and ivermectin (Type: EXPERIMENTAL): 400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).